CASBF (CanSino Biologics) Institutional Ownership: 5.66% (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASBF CanSino Biologics Inc CASBF
69 GF Score
Price $2.60
GF Value $8.73
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is CanSino Biologics Institutional Ownership?

CanSino Biologics CASBF 69 Institutional Ownership is 5.66% as of Jul. 15, 2026. GuruFocus rates CASBF with a GF Score™ of 69/100 and a GF Value™ of $8.73 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CanSino Biologics's institutional ownership is 5.66%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CanSino Biologics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CanSino Biologics's Float Percentage Of Total Shares Outstanding is 0.00%.

CanSino Biologics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for CanSino Biologics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CanSino Biologics Institutional Ownership Chart

CanSino Biologics Historical Data

The historical data trend for CanSino Biologics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 5.76 5.81 5.88 8.14 8.19 8.23 8.20 8.17 8.12 8.06
CASBF
69GF Score
CanSino Biologics Inc CASBF
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CanSino Biologics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 5.66% mean?
CanSino Biologics (CASBF) has a Institutional Ownership of 5.66% as of Jul. 15, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on CanSino Biologics and its competitors.
Is CanSino Biologics' Institutional Ownership too high?
CanSino Biologics' current Institutional Ownership is 5.66%. Overall, CanSino Biologics has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CanSino Biologics' Institutional Ownership compare to ZTS and UTHR?
CanSino Biologics' Institutional Ownership of 5.66% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on CanSino Biologics and its competitors. CanSino Biologics's current Institutional Ownership is 5.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanSino Biologics stock overvalued right now?
Based on GuruFocus' analysis, CanSino Biologics (CASBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $8.73, compared to a current price of $2.60 — trading 70.2% below its estimated fair value. The current Institutional Ownership is 5.66%. CanSino Biologics' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For CanSino Biologics (CASBF), the current Institutional Ownership is 5.66% as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CanSino Biologics (CASBF) Overvalued in 2026?

Based on GuruFocus' analysis, CanSino Biologics stock appears to be undervalued. The current stock price of $2.60 is trading 70.2% below its estimated GF Value™ of $8.73. GuruFocus considers CanSino Biologics to be Significantly Undervalued.

Key valuation signals for CASBF:

  • Institutional Ownership: 5.66%
  • GF Value™: $8.73 vs. price of $2.60 (70.2% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the CASBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CanSino Biologics Business Description

Address 185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. The company has a broad portfolio of vaccines and vaccine candidates for several disease areas. Its commercial-stage products are Menhycia and Menphecia, iPneucia, Convidecia and Convidecia Air, and XBB.1.5 Variant, and Ad5-EBOV. The company's clinical-stage products include Tetanus Vaccine, DTcP Infant, Tdcp Adolescent and Adult, Recombinant Poliomyelitis Vaccine, PBPV, and Recombinant Zoster Vaccine, among others. Additionally, it has various vaccine candidates in pre-clinical programs, targeting diseases such as influenza, meningitis, pneumonia, and others. Geographically, the company generates maximum revenue from the People's Republic of China.
69GF Score

Get the complete analysis for CASBF

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.60
Price
$8.73
GF Value